Analysis of EpCAM positive cells isolated from sentinel lymph nodes of breast cancer patients identifies subpopulations of cells with distinct transcription profiles

Breast Cancer Research

Volumn 13, Issue 4, 2011, Pages

  Tveito, Siri ^a   Andersen, Kristin ^a   Kåresen, Rolf ^b,c   Fodstad, Øystein ^a,c  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; CELL SURFACE PROTEIN; EPITHELIAL CELL ADHESION MOLECULE; MAMMAGLOBIN; MATRIX METALLOPROTEINASE; MUCIN 1; OSTEONECTIN; TUMOR MARKER; UVOMORULIN; VIMENTIN; AGR2 PROTEIN, HUMAN; CADHERIN; CELL ADHESION MOLECULE; EPCAM PROTEIN, HUMAN; MUC1 PROTEIN, HUMAN; MUCIN; MUCL1 PROTEIN, HUMAN; PROTEIN; TFF1 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR SUPPRESSOR PROTEIN;

ARTICLE; BREAST CANCER; BREAST EPITHELIUM; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CELL FRACTIONATION; CELL ISOLATION; CELL SUBPOPULATION; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOMAGNETIC SEPARATION; MAJOR CLINICAL STUDY; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE; AXILLA; BREAST TUMOR; EPITHELIUM CELL; FEMALE; GENETICS; LYMPH NODE; LYMPH NODE METASTASIS; METABOLISM; METHODOLOGY; PATHOLOGY; REPRODUCIBILITY; SENTINEL LYMPH NODE BIOPSY;

ANTIGENS, NEOPLASM; AXILLA; BREAST NEOPLASMS; CADHERINS; CELL ADHESION MOLECULES; EPITHELIAL CELLS; FEMALE; HUMANS; IMMUNOMAGNETIC SEPARATION; LYMPH NODES; LYMPHATIC METASTASIS; MUCIN-1; MUCINS; OSTEONECTIN; PROTEINS; REPRODUCIBILITY OF RESULTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SENTINEL LYMPH NODE BIOPSY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS; VIMENTIN;

EID: 79961119879     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr2922     Document Type: Article

References (59)

1. Carter CL, Allen C, Henson DE. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989, 63:181-187. 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO;2-H, 2910416.
2. Fisher B, Bauer M, Wickerham DL, Redmond CK, Fisher ER, Cruz AB, Foster R, Gardner B, Lerner H, Margolese R, et al. Relation of number of positive axillary nodes to the prognosis of patients with primary breast cancer. An NSABP update. Cancer 1983, 52:1551-1557. 10.1002/1097-0142(19831101)52:9<1551::AID-CNCR2820520902>3.0.CO;2-3, 6352003.
3. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, Ruby SG, O'Malley F, Simpson JF, Connolly JL, Hayes DF, Edge SB, Lichter A, Schnitt SJ. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000, 124:966-978.
4. Krag D, Weaver D, Ashikaga T, Moffat F, Klimberg VS, Shriver C, Feldman S, Kusminsky R, Gadd M, Kuhn J, Harlow S, Beitsch P. The sentinel node in breast cancer--a multicenter validation study. N Engl J Med 1998, 339:941-946. 10.1056/NEJM199810013391401, 9753708.
5. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997, 15:2345-2350.
6. Cote RJ, Peterson HF, Chaiwun B, Gelber RD, Goldhirsch A, Castiglione-Gertsch M, Gusterson B, Neville AM. Role of immunohistochemical detection of lymph-node metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999, 354:896-900. 10.1016/S0140-6736(98)11104-2, 10489948.
7. Cserni G. Metastases in axillary sentinel lymph nodes in breast cancer as detected by intensive histopathological work up. J Clin Pathol 1999, 52:922-924. 10.1136/jcp.52.12.922, 501663, 10711258.
8. Groen RS, Oosterhuis AW, Boers JE. Pathologic examination of sentinel lymph nodes in breast cancer by a single haematoxylin-eosin slide versus serial sectioning and immunocytokeratin staining: clinical implications. Breast Cancer Res Treat 2007, 105:1-5. 2001221, 17221160.
9. Motomura K, Komoike Y, Inaji H, Hasegawa Y, Kasugai T, Noguchi S, Koyama H. Multiple sectioning and immunohistochemical staining of sentinel nodes in patients with breast cancer. Br J Surg 2002, 89:1032-1034. 10.1046/j.1365-2168.2002.02177.x, 12153631.
10. de Boer M, van Deurzen CH, van Dijck JA, Borm GF, van Diest PJ, Adang EM, Nortier JW, Rutgers EJ, Seynaeve C, Menke-Pluymers MB, Bult P, Tjan-Heijnen VC. Micrometastases or isolated tumor cells and the outcome of breast cancer. New Engl J Med 2009, 361:653-663. 10.1056/NEJMoa0904832, 19675329.
11. Reed J, Rosman M, Verbanac KM, Mannie A, Cheng Z, Tafra L. Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina University/Anne Arundel Medical Center Sentinel Node Multicenter Study. J Am Coll Surg 2009, 208:333-340. 10.1016/j.jamcollsurg.2008.10.036, 19317993.
12. Tan LK, Giri D, Hummer AJ, Panageas KS, Brogi E, Norton L, Hudis C, Borgen PI, Cody HS. Occult axillary node metastases in breast cancer are prognostically significant: results in 368 node-negative patients with 20-year follow-up. J Clin Oncol 2008, 26:1803-1809. 10.1200/JCO.2007.12.6425, 18332473.
13. Querzoli P, Pedriali M, Rinaldi R, Lombardi AR, Biganzoli E, Boracchi P, Ferretti S, Frasson C, Zanella C, Ghisellini S, Ambrogi F, Antolini L, Piantelli M, Iacobelli S, Marubini E, Alberti S, Nenci I. Axillary lymph node nanometastases are prognostic factors for disease-free survival and metastatic relapse in breast cancer patients. Clin Cancer Res 2006, 12:6696-6701. 10.1158/1078-0432.CCR-06-0569, 17121888.
14. Brunsvig PF, Flatmark K, Aamdal S, Hoifodt H, Le H, Jakobsen E, Sandstad B, Fodstad O. Bone marrow micrometastases in advanced stage non-small cell lung carcinoma patients. Lung Cancer (Amsterdam, Netherlands) 2008, 61:170-176.
15. Faye RS, Aamdal S, Hoifodt HK, Jacobsen E, Holstad L, Skovlund E, Fodstad O. Immunomagnetic detection and clinical significance of micrometastatic tumor cells in malignant melanoma patients. Clin Cancer Res 2004, 10:4134-4139. 10.1158/1078-0432.CCR-03-0408, 15217950.
16. Eide N, Faye RS, Hoifodt HK, Overgaard R, Jebsen P, Kvalheim G, Fodstad O. Immunomagnetic detection of micrometastatic cells in bone marrow in uveal melanoma patients. Acta Ophthalmol 2009, 87:830-836. 10.1111/j.1755-3768.2008.01378.x, 19055657.
17. Tveito S, Maelandsmo GM, Hoifodt HK, Rasmussen H, Fodstad O. Specific isolation of disseminated cancer cells: a new method permitting sensitive detection of target molecules of diagnostic and therapeutic value. Clin Exp Metastasis 2007, 24:317-327. 10.1007/s10585-006-9052-8, 17530423.
18. Hardingham JE, Kotasek D, Farmer B, Butler RN, Mi JX, Sage RE, Dobrovic A. Immunobead-PCR: a technique for the detection of circulating tumor cells using immunomagnetic beads and the polymerase chain reaction. Cancer Res 1993, 53:3455-3458.
19. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol 2007, 171:386-395. 10.2353/ajpath.2007.070152, 1934518, 17600130.
20. van der Gun BT, Melchers LJ, Ruiters MH, de Leij LF, McLaughlin PM, Rots MG. EpCAM in carcinogenesis: the good, the bad or the ugly. Carcinogenesis 2010, 31:1913-1921. 10.1093/carcin/bgq187, 20837599.
21. Cimino A, Halushka M, Illei P, Wu X, Sukumar S, Argani P. Epithelial cell adhesion molecule (EpCAM) is overexpressed in breast cancer metastases. Breast Cancer Res Treat 2010, 123:701-708. 10.1007/s10549-009-0671-z, 3042397, 20012351.
22. Sieuwerts AM, Kraan J, Bolt J, van der Spoel P, Elstrodt F, Schutte M, Martens JW, Gratama JW, Sleijfer S, Foekens JA. Anti-epithelial cell adhesion molecule antibodies and the detection of circulating normal-like breast tumor cells. J Natl Cancer Inst 2009, 101:61-66. 2639293, 19116383.
23. Vlad AM, Kettel JC, Alajez NM, Carlos CA, Finn OJ. MUC1 immunobiology: from discovery to clinical applications. Adv Immunol 2004, 82:249-293.
24. Eaton MC, Hardingham JE, Kotasek D, Dobrovic A. Immunobead RT-PCR: a sensitive method for detection of circulating tumor cells. Biotechniques 1997, 22:100-105.
25. Norwegian breast cancer group. , http://nbcg.no/
26. Delahaye M, van der Ham F, van der Kwast TH. Complementary value of five carcinoma markers for the diagnosis of malignant mesothelioma, adenocarcinoma metastasis, and reactive mesothelium in serous effusions. Diagn Cytopathol 1997, 17:115-120. 10.1002/(SICI)1097-0339(199708)17:2<115::AID-DC6>3.0.CO;2-F, 9258618.
27. Flatmark K, Bjornland K, Johannessen HO, Hegstad E, Rosales R, Harklau L, Solhaug JH, Faye RS, Soreide O, Fodstad O. Immunomagnetic detection of micrometastatic cells in bone marrow of colorectal cancer patients. Clin Cancer Res 2002, 8:444-449.
28. Universal ProbeLibrary Assay Design Center. , https://www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=uplct_030000
29. Zehentner BK, Carter D. Mammaglobin: a candidate diagnostic marker for breast cancer. Clin Biochem 2004, 37:249-257. 10.1016/j.clinbiochem.2003.11.005, 15003725.
30. Wang Z, Hao Y, Lowe AW. The adenocarcinoma-associated antigen, AGR2, promotes tumor growth, cell migration, and cellular transformation. Cancer Res 2008, 68:492-497. 10.1158/0008-5472.CAN-07-2930, 18199544.
31. Amiry N, Kong X, Muniraj N, Kannan N, Grandison PM, Lin J, Yang Y, Vouyovitch CM, Borges S, Perry JK, Mertani HC, Zhu T, Liu D, Lobie PE. Trefoil factor-1 (TFF1) enhances oncogenicity of mammary carcinoma cells. Endocrinology 2009, 150:4473-4483. 10.1210/en.2009-0066, 19589871.
32. Miksicek RJ, Myal Y, Watson PH, Walker C, Murphy LC, Leygue E. Identification of a novel breast- and salivary gland-specific, mucin-like gene strongly expressed in normal and tumor human mammary epithelium. Cancer Res 2002, 62:2736-2740.
33. Thiery JP. Epithelial-mesenchymal transitions in development and pathologies. Curr Opin Cell Biol 2003, 15:740-746. 10.1016/j.ceb.2003.10.006, 14644200.
34. Thiery JP, Acloque H, Huang RY, Nieto MA. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890. 10.1016/j.cell.2009.11.007, 19945376.
35. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1428. 10.1172/JCI39104, 2689101, 19487818.
36. Putz E, Witter K, Offner S, Stosiek P, Zippelius A, Johnson J, Zahn R, Riethmuller G, Pantel K. Phenotypic characteristics of cell lines derived from disseminated cancer cells in bone marrow of patients with solid epithelial tumors: establishment of working models for human micrometastases. Cancer Res 1999, 59:241-248.
37. Chlenski A, Cohn SL. Modulation of matrix remodeling by SPARC in neoplastic progression. Semin Cell Dev Biol 2010, 21:55-65. 10.1016/j.semcdb.2009.11.018, 19958839.
38. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, Campbell LL, Polyak K, Brisken C, Yang J, Weinberg RA. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715. 10.1016/j.cell.2008.03.027, 2728032, 18485877.
39. Tamaki Y, Akiyama F, Iwase T, Kaneko T, Tsuda H, Sato K, Ueda S, Mano M, Masuda N, Takeda M, Tsujimoto M, Yoshidome K, Inaji H, Nakajima H, Komoike Y, Kataoka TR, Nakamura S, Suzuki K, Tsugawa K, Wakasa K, Okino T, Kato Y, Noguchi S, Matsuura N. Molecular detection of lymph node metastases in breast cancer patients: results of a multicenter trial using the one-step nucleic acid amplification assay. Clin Cancer Res 2009, 15:2879-2884. 10.1158/1078-0432.CCR-08-1881, 19351770.
40. Martin Martinez MD, Veys I, Majjaj S, Lespagnard L, Schobbens JC, Rouas G, Filippov V, Noterman D, Hertens D, Feoli F, Bourgeois P, Durbecq V, Larsimont D, Nogaret JM. Clinical validation of a molecular assay for intra-operative detection of metastases in breast sentinel lymph nodes. Eur J Surg Oncol 2009, 35:387-392. 10.1016/j.ejso.2008.05.008, 18639429.
41. Viale G, Dell'Orto P, Biasi MO, Stufano V, De Brito Lima LN, Paganelli G, Maisonneuve P, Vargo JM, Green G, Cao W, Swijter A, Mazzarol G. Comparative evaluation of an extensive histopathologic examination and a real-time reverse-transcription-polymerase chain reaction assay for mammaglobin and cytokeratin 19 on axillary sentinel lymph nodes of breast carcinoma patients. Ann Surg 2008, 247:136-142. 10.1097/SLA.0b013e318157d22b, 18156933.
42. Effenberger KE, Borgen E, Eulenburg CZ, Bartkowiak K, Grosser A, Synnestvedt M, Kaaresen R, Brandt B, Nesland JM, Pantel K, Naume B. Detection and clinical relevance of early disseminated breast cancer cells depend on their cytokeratin expression pattern. Breast Cancer Res Treat 2011, 125:729-738. 10.1007/s10549-010-0911-2, 20449649.
43. Oncolex database. , http://oncolex.no
44. Weckermann D, Polzer B, Ragg T, Blana A, Schlimok G, Arnholdt H, Bertz S, Harzmann R, Klein CA. Perioperative activation of disseminated tumor cells in bone marrow of patients with prostate cancer. J Clin Oncol 2009, 27:1549-1556. 10.1200/JCO.2008.17.0563, 19237635.
45. Husemann Y, Geigl JB, Schubert F, Musiani P, Meyer M, Burghart E, Forni G, Eils R, Fehm T, Riethmuller G, Klein CA. Systemic spread is an early step in breast cancer. Cancer Cell 2008, 13:58-68. 10.1016/j.ccr.2007.12.003, 18167340.
46. Pachmann K, Camara O, Kavallaris A, Krauspe S, Malarski N, Gajda M, Kroll T, Jorke C, Hammer U, Altendorf-Hofmann A, Rabenstein C, Pachmann U, Runnebaum I, Hoffken K. Monitoring the response of circulating epithelial tumor cells to adjuvant chemotherapy in breast cancer allows detection of patients at risk of early relapse. J Clin Oncol 2008, 26:1208-1215. 10.1200/JCO.2007.13.6523, 18323545.
47. Watson MA, Ylagan LR, Trinkaus KM, Gillanders WE, Naughton MJ, Weilbaecher KN, Fleming TP, Aft RL. Isolation and molecular profiling of bone marrow micrometastases identifies TWIST1 as a marker of early tumor relapse in breast cancer patients. Clin Cancer Res 2007, 13:5001-5009. 10.1158/1078-0432.CCR-07-0024, 2680916, 17785550.
48. Woelfle U, Breit E, Zafrakas K, Otte M, Schubert F, Muller V, Izbicki JR, Loning T, Pantel K. Bi-specific immunomagnetic enrichment of micrometastatic tumour cell clusters from bone marrow of cancer patients. J Immunol Methods 2005, 300:136-145. 10.1016/j.jim.2005.03.006, 15907331.
49. Riethdorf S, Fritsche H, Muller V, Rau T, Schindlbeck C, Rack B, Janni W, Coith C, Beck K, Janicke F, Jackson S, Gornet T, Cristofanilli M, Pantel K. Detection of circulating tumor cells in peripheral blood of patients with metastatic breast cancer: a validation study of the CellSearch system. Clin Cancer Res 2007, 13:920-928. 10.1158/1078-0432.CCR-06-1695, 17289886.
50. Allard WJ, Matera J, Miller MC, Repollet M, Connelly MC, Rao C, Tibbe AG, Uhr JW, Terstappen LW. Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res 2004, 10:6897-6904. 10.1158/1078-0432.CCR-04-0378, 15501967.
51. Cristofanilli M. The biological information obtainable from circulating tumor cells. Breast 2009, 18(Suppl 3):S38-40.
52. Rao CG, Chianese D, Doyle GV, Miller MC, Russell T, Sanders RA, Terstappen LW. Expression of epithelial cell adhesion molecule in carcinoma cells present in blood and primary and metastatic tumors. Int J Oncol 2005, 27:49-57.
53. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol 2009, 6:339-351. 10.1038/nrclinonc.2009.44, 19399023.
54. Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res 2009, 11:R46. 10.1186/bcr2333, 2750105, 19589136.
55. Raimondi C, Gradilone A, Naso G, Vincenzi B, Petracca A, Nicolazzo C, Palazzo A, Saltarelli R, Spremberg F, Cortesi E, Gazzaniga P. Epithelial-mesenchymal transition and stemness features in circulating tumor cells from breast cancer patients. Breast Cancer Res Treat 2011,
56. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lonning P, Borresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
57. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
58. Park SY, Lee HE, Li H, Shipitsin M, Gelman R, Polyak K. Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer. Clin Cancer Res 16:876-887. 2818503, 20103682.
59. Tomaskovic-Crook E, Thompson EW, Thiery JP. Epithelial to mesenchymal transition and breast cancer. Breast Cancer Res 2009, 11:213. 10.1186/bcr2416, 2815537, 19909494.